SD BioSensor (137310) Fundamentals 2026 — Revenue Analysis | SniperIQ
SD BioSensor (137310) is a KR-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ₩696.2B, trading at ₩5820.00 on the KSC. This SniperIQ fundamentals page covers SD BioSensor's valuation, profitability (net margin -65.5%), revenue (₩710.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SD BioSensor's market cap?
SD BioSensor (137310) has a market capitalization of approximately ₩696.2B, trading at ₩5820.00 on the KSC. Market cap moves with the live share price.
What is SD BioSensor's P/E ratio?
SD BioSensor's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SD BioSensor?
SD BioSensor runs a net profit margin of -65.5%, a gross margin of 29.4%, and an operating margin of -11.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SD BioSensor generate?
SD BioSensor reported revenue of ₩710.6B for fiscal year 2025, with net income of -₩521.4B and earnings per share (EPS) of -4282.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SD BioSensor pay a dividend?
SD BioSensor offers a trailing dividend yield of about 3.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is SD BioSensor financially healthy?
SD BioSensor carries a debt-to-equity ratio of 0.13x and a current ratio of 5.07x, with a market beta of 0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SD BioSensor a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SD BioSensor (137310) the key facts are: market cap ₩696.2B, revenue ₩710.6B, 52-week range 5820-10930. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SD BioSensor's full fundamentals live
Get SD BioSensor's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.